Oral PCSK9 Inhibitor Tied to LDL-C Drop
-
by Kerri Miller
November 24, 2025
-
3 min
9 Key Takeaways
-
1
Enlicitide is a PCSK9 inhibitor.
-
2
Achieved a 5
-
3
2% reduction in LDL-C compared to placebo.
-
4
Trial involved 303 adults with HeFH across 17 countries.
-
5
Participants were on moderate to high-intensity statins.
-
6
LDL-C reductions sustained throughout the trial duration.
-
7
Adverse event rates were similar between groups.
-
8
Ongoing separate outcomes trial will assess cardiovascular effects.
-
9
Study funded by Merck Sharp & Dohme LLC.
Enlicitide, an oral macrocyclic peptide and PCSK9 inhibitor, was evaluated in a phase 3 trial involving 303 adults with heterozygous familial hypercholesterolemia (HeFH). This study revealed a significant 58.2% reduction in LDL-C levels after 24 weeks of treatment compared to placebo. The trial demonstrated that enlicitide is effective in lowering cholesterol levels while maintaining a safety profile similar to placebo, with only mild adverse effects observed. Participants were already on high-intensity statins, and the trial is ongoing to determine long-term cardiovascular outcomes.
Listen Tab content
